Arca
Skip to content
Tools
Tools

GRM5: Metabotropic glutamate receptor 5

G protein-coupled receptor for glutamate.

  • Drugs that act on it: 9
  • Approved: 0
  • In phases 1 to 3: 9
  • Sponsors: 6

Who is on it, and how far along

Every drug ChEMBL records acting on GRM5, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 7
  • Other 2

Approved0

    Phase 30

      Phase 28

      • Basimglurant
      • Mavoglurant
      • AZD2066
      • AZD2516
      • Dasolampanel etibutil
      • Dipraglurant
      • Raseglurant
      • STX107

      Phase 11

      • RG7342

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • Addex Pharma S.A.222%
      • Noema Pharma AG111%
      • Seaside Therapeutics, Inc.111%

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 5 of 9 act as: Metabotropic glutamate receptor 5 modulator; the rest name their own mechanism.
      BasimglurantPhase 2Noema Pharma AGSmall moleculeModulator1
      MavoglurantPhase 2Novartis PharmaceuticalsSmall moleculeAntagonistMetabotropic glutamate receptor 5 antagonist1
      AZD2066Phase 2AstraZeneca PharmaceuticalsSmall moleculeModulator0
      AZD2516Phase 2AstraZeneca PharmaceuticalsOtherNegative allosteric modulatorMetabotropic glutamate receptor 5 negative allosteric modulator0
      Dasolampanel etibutilPhase 2Eli LillySmall moleculeAntagonistMetabotropic glutamate receptor 5 antagonist0
      DipraglurantPhase 2Addex Pharma S.A.Small moleculeModulator0
      RaseglurantPhase 2Addex Pharma S.A.Small moleculeModulator0
      STX107Phase 2Seaside Therapeutics, Inc.Small moleculeNegative allosteric modulatorMetabotropic glutamate receptor 5 negative allosteric modulator0
      RG7342Phase 1—OtherModulator0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 2 in all, from ClinicalTrials.gov.
      Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy DrinkersMavoglurantPhase 1RecruitingYale UniversityNov 18, 2023
      An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.BasimglurantPhase 2 / Phase 3Active, not recruitingNoema Pharma AGFeb 1, 2022

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Benign neoplasm of eye0.42
      • Retinal detachment0.41
      • Smoking initiation0.40
      • Skin neoplasm0.39
      • Skin disorder0.34
      • Skin reaction0.32

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3227, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P41594, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.